PT2968208T - Tratamento da cataplexia - Google Patents
Tratamento da cataplexiaInfo
- Publication number
- PT2968208T PT2968208T PT147780886T PT14778088T PT2968208T PT 2968208 T PT2968208 T PT 2968208T PT 147780886 T PT147780886 T PT 147780886T PT 14778088 T PT14778088 T PT 14778088T PT 2968208 T PT2968208 T PT 2968208T
- Authority
- PT
- Portugal
- Prior art keywords
- cataplexy
- treatment
- Prior art date
Links
- 208000001573 Cataplexy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778998P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2968208T true PT2968208T (pt) | 2022-10-28 |
Family
ID=51530017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147780886T PT2968208T (pt) | 2013-03-13 | 2014-03-12 | Tratamento da cataplexia |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US9359290B2 (enExample) |
| EP (1) | EP2968208B1 (enExample) |
| JP (2) | JP6530741B2 (enExample) |
| KR (1) | KR102192554B1 (enExample) |
| CN (1) | CN105431142B (enExample) |
| AU (1) | AU2014248849B2 (enExample) |
| BR (1) | BR112015022197B1 (enExample) |
| CA (1) | CA2905457A1 (enExample) |
| DK (1) | DK2968208T3 (enExample) |
| ES (1) | ES2927675T3 (enExample) |
| HR (1) | HRP20221018T1 (enExample) |
| HU (1) | HUE060060T2 (enExample) |
| MX (1) | MX381381B (enExample) |
| MY (1) | MY177740A (enExample) |
| PH (1) | PH12015502075A1 (enExample) |
| PT (1) | PT2968208T (enExample) |
| RU (2) | RU2689984C2 (enExample) |
| SG (1) | SG11201507121RA (enExample) |
| SI (1) | SI2968208T1 (enExample) |
| TW (2) | TWI663971B (enExample) |
| WO (1) | WO2014164969A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133393A1 (en) * | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| BR112015022197B1 (pt) * | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
| CN110638804A (zh) | 2013-07-18 | 2020-01-03 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3036071A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| US10195151B2 (en) * | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| CN110049966A (zh) | 2016-10-06 | 2019-07-23 | 杰资制药国际三期有限公司 | 氨基甲酰基苯丙氨醇化合物及其用途 |
| JP2020528075A (ja) | 2017-06-02 | 2020-09-17 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 過度の眠気を処置するための方法および組成物 |
| CA3071779A1 (en) | 2017-07-31 | 2019-02-07 | Jazz Pharmaceuticals Ireland Limited | Carbamoyl phenylalaninol analogs and uses thereof |
| AU2018331326A1 (en) * | 2017-09-12 | 2020-03-19 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of narcolepsy |
| EP3746065A4 (en) | 2018-01-29 | 2022-02-16 | Cognos Therapeutics Inc. | INTRATUMORAL ADMINISTRATION OF BORTEZOMIB |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| KR20210071046A (ko) * | 2018-10-15 | 2021-06-15 | 액섬 테라퓨틱스, 인크. | 기면증 치료를 위한 레복세틴의 용도 |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| CA3163505A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| WO2025006965A1 (en) | 2023-06-29 | 2025-01-02 | Axsome Therapeutics, Inc. | Methods of administering solriamfetol to lactating women |
| WO2025042959A1 (en) * | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US178429A (en) * | 1876-06-06 | Improvement in hulling-machines | ||
| ZA943862B (en) | 1993-06-10 | 1995-12-04 | Lilly Co Eli | Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| PT873308E (pt) | 1996-10-10 | 2002-06-28 | Sk Corp | Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos |
| WO1998017636A1 (en) | 1996-10-22 | 1998-04-30 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| MXPA06011410A (es) * | 2004-03-31 | 2007-04-20 | Johnson & Johnson | Compuestos heterociclicos sin imidazol como moduladores de receptor de histamina h3. |
| BRPI0515645A (pt) * | 2004-09-07 | 2008-03-04 | Orphan Medical Inc | métodos terapêuticos, composições, compostos e usos de compostos |
| CA2587481A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Phenylalkylamino carbamates adjunctive therapy for depression |
| WO2006133393A1 (en) | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| CA2612672C (en) | 2005-06-22 | 2014-10-14 | Janssen Pharmaceutica, N.V. | Treatment for sexual dysfunction |
| EP1928451B1 (en) | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| KR20090082213A (ko) | 2006-10-13 | 2009-07-29 | 얀센 파마슈티카 엔.브이. | 페닐알킬아미노 카바메이트 조성물 |
| CA2669088C (en) * | 2006-11-10 | 2016-04-05 | Dimerix Bioscience Pty Ltd | Detection system and uses therefor |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| BR112015022197B1 (pt) * | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
-
2014
- 2014-03-12 BR BR112015022197-1A patent/BR112015022197B1/pt active IP Right Grant
- 2014-03-12 US US14/205,423 patent/US9359290B2/en active Active
- 2014-03-12 TW TW103108612A patent/TWI663971B/zh active
- 2014-03-12 AU AU2014248849A patent/AU2014248849B2/en active Active
- 2014-03-12 PT PT147780886T patent/PT2968208T/pt unknown
- 2014-03-12 EP EP14778088.6A patent/EP2968208B1/en active Active
- 2014-03-12 RU RU2015143610A patent/RU2689984C2/ru active
- 2014-03-12 MY MYPI2015703166A patent/MY177740A/en unknown
- 2014-03-12 JP JP2016501395A patent/JP6530741B2/ja active Active
- 2014-03-12 ES ES14778088T patent/ES2927675T3/es active Active
- 2014-03-12 HR HRP20221018TT patent/HRP20221018T1/hr unknown
- 2014-03-12 HU HUE14778088A patent/HUE060060T2/hu unknown
- 2014-03-12 CA CA2905457A patent/CA2905457A1/en not_active Abandoned
- 2014-03-12 RU RU2019114940A patent/RU2019114940A/ru not_active Application Discontinuation
- 2014-03-12 WO PCT/US2014/023969 patent/WO2014164969A1/en not_active Ceased
- 2014-03-12 SG SG11201507121RA patent/SG11201507121RA/en unknown
- 2014-03-12 DK DK14778088.6T patent/DK2968208T3/da active
- 2014-03-12 TW TW108107074A patent/TWI684450B/zh active
- 2014-03-12 KR KR1020157027978A patent/KR102192554B1/ko active Active
- 2014-03-12 SI SI201431991T patent/SI2968208T1/sl unknown
- 2014-03-12 MX MX2015012644A patent/MX381381B/es unknown
- 2014-03-12 CN CN201480027152.9A patent/CN105431142B/zh active Active
-
2015
- 2015-09-11 PH PH12015502075A patent/PH12015502075A1/en unknown
-
2016
- 2016-05-09 US US15/149,478 patent/US9585863B2/en active Active
-
2017
- 2017-01-30 US US15/419,133 patent/US10259780B2/en active Active
-
2019
- 2019-03-20 US US16/359,446 patent/US11072579B2/en active Active
- 2019-05-17 JP JP2019093823A patent/JP2019147830A/ja active Pending
-
2021
- 2021-07-23 US US17/383,707 patent/US11713292B2/en active Active
-
2023
- 2023-06-19 US US18/337,299 patent/US12162821B2/en active Active
-
2024
- 2024-11-04 US US18/935,803 patent/US20250059135A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287516A (en) | Medicinal uses of empagliflozin | |
| SG11201507121RA (en) | Treatment of cataplexy | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| IL241102B (en) | Medicinal uses of empagliflozin | |
| HUE064634T2 (hu) | Kardiovaszkuláris betegségek kezelése | |
| PL2981271T3 (pl) | Zastosowania terapeutyczne empagliflozyny | |
| ZA201508515B (en) | Treatment of coal | |
| IL241096A0 (en) | Treatment methods | |
| GB201403083D0 (en) | Treatment of cancer | |
| ZA201601626B (en) | Treatment of gases | |
| GB201314303D0 (en) | Treatment of HPV | |
| GB2525530B (en) | Treatment of hard surfaces | |
| GB201320653D0 (en) | Treatment of plants | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| GB201301722D0 (en) | Quantifcation of bacteria |